Stockscreener 앱 받기
2.53
0.80%
0.02
시간 외 거래:
2.53
전일 마감가:
$2.51
열려 있는:
$2.5098
하루 거래량:
15,240
Relative Volume:
0.85
시가총액:
$72.41M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-2.32%
1개월 성능:
-7.33%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$2.33
$2.59
1주일 범위
$2.33
$2.66
52주 변동 폭
$2.33
$3.09
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
명칭
Insight Molecular Diagnostics Inc
전화
949-409-7600
주소
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
IMDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
2.53 | 71.84M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
492.72 | 184.93B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
205.82 | 147.00B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
647.09 | 51.77B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
125.66 | 35.50B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
190.81 | 32.08B | 15.70B | 1.24B | 2.01B | 6.91 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-28 | 개시 | Lake Street | Buy |
| 2022-05-24 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-03-17 | 재개 | Needham | Buy |
| 2021-01-07 | 업그레이드 | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | 개시 | BTIG Research | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | 재확인 | The Benchmark Company | Speculative Buy |
| 2020-07-01 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | 개시 | Needham | Buy |
| 2019-02-13 | 개시 | Piper Jaffray | Overweight |
| 2019-01-29 | 업그레이드 | Janney | Neutral → Buy |
| 2018-12-19 | 재개 | Lake Street | Buy |
모두보기
Insight Molecular Diagnostics Inc 주식(IMDX)의 최신 뉴스
iMDx to Participate in NYC Investment Conferences September 811 - GlobeNewswire
iMDx Announces Participation in NYC Investment Conferences - AInvest
Molecular Diagnostics Leader iMDx Announces Double-Header NYC Investor Conference Schedule for September - Stock Titan
iMDx CFO Andrea James discusses democratizing molecular diagnostics in podcast episode. - AInvest
IMDX CFO Andrea James Featured in Empowered Patient Podcast on Democratizing Molecular Diagnostics - MarketScreener
HIV Diagnostics Market Size, Share & Forecast, 2025–2034 - Global Market Insights Inc.
Insight Molecular Diagnostics: Pioneering the Next Generation of Transplant Rejection Testing and FDA Readiness - AInvest
Veterinary Molecular Diagnostics Market on Track for Massive Expansion by 2035, Forecasts Reveal. - newstrail.com
Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Insight Molecular Diagnostics (IMDX) - The Globe and Mail
Insight Molecular Diagnostics Inc. shares rise 12.92% intraday after Myriad Genetics appoints new CFO. - AInvest
Molecular Diagnostics Market Evolving Rapidly from 2025 to 2032 | F. Hoffmann-La Roche Ltd, Illumina, Inc. - openPR.com
Insight Molecular: Needham Reiterates Buy Rating with $4.25 PT - AInvest
Insight Molecular Diagnostics: Paving the Next Frontier in Transplant Rejection Testing with FDA-Ready Innovation - AInvest
IMDX’s GraftAssureDx Study: A Game-Changer in Kidney Transplant Monitoring? - TipRanks
Insight Molecular Diagnostics Inc. shares rise 1.21% intraday after Caris Life Sciences validates MI Cancer Seek® assay. - AInvest
Insight Molecular Diagnostics Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Insight Molecular Diagnostics : With Q&A (insight molecular diagnostics inc imdx us q2 2025 earnings call 11 august 2025 5 00 pm et) - MarketScreener
Lake Street Sticks to Their Buy Rating for Insight Molecular Diagnostics (IMDX) - The Globe and Mail
Insight Molecular Diagnostics Inc. shares fall 1.53% intraday after reporting a Q2 loss of $9.7 million. - AInvest
Insight Molecular Diagnostics Inc (IMDX) Q2 2025 Earnings Call Highlights: Strategic Advances ... - Yahoo Finance
Needham reiterates Buy rating on Insight Molecular Diagnostics stock By Investing.com - Investing.com Nigeria
Needham reiterates Buy rating on Insight Molecular Diagnostics stock - Investing.com India
Insight Molecular Diagnostics: Promising Future with GraftAssureIQ and Strategic Expansion - TipRanks
Insight Molecular Diagnostics: Q2 Earnings Snapshot - Connecticut Post
Insight Molecular Diagnostics Reports Q2 2025 Progress - TipRanks
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch - Santé log
Earnings call transcript: Insight Molecular Diagnostics Q2 2025 reveals strategic advancements - Investing.com Canada
Insight Molecular Diagnostics Reports Q2 Loss of $9.7 Million - AInvest
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx L - GuruFocus
IMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference - 富途牛牛
Insight Molecular Diagnostics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Insight Molecular Diagnostics Inc.Common Stock (Nasdaq:IMDX) Stock Quote - FinancialContent
Molecular Diagnostics Market Overview: Growth Factors to 2035 - MarketReports.us
PCR Molecular Diagnostics Market Global Forecast 2025–2032: Sector-Wise Insights - newstrail.com
Insight Molecular Diagnostics Inc. shares rise 8.81% premarket after QIAGEN's solid Q2 2025 results. - AInvest
iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference - The Manila Times
iMDx to Release Second Quarter 2025 Results on August 11, - GlobeNewswire
iMDx Announces Two Major Investor Events: Q2 Earnings and Needham Conference Back-to-Back - Stock Titan
Diagnostic Contract Manufacturing Market Forecast 2025–2034: Key Metrics and Strategic Insights - WhaTech
IMDX World Transplant Congress Late-Breaking Data - GlobeNewswire
Revolutionary Transplant Test Achieves 79% Accuracy, Nearly Doubles Industry Standard in Detecting Organ Rejection - Stock Titan
U.S., Europe, and Asia Pacific Molecular Diagnostics Market - openPR.com
iMDx to Host Virtual KOL Event to Discuss its In-House - GlobeNewswire
Vanderbilt Professor Reveals Game-Changing In-House Kidney Transplant Testing Technology at Expert Event - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: ProMIS Neurosciences (PMN), Bruker (BRKR) - The Globe and Mail
Insight Molecular Diagnostics Inc. shares fall 3.16% intraday as ImmunoPrecise Antibodies Ltd. announces new findings. - AInvest
Insight Molecular Diagnostics Inc. shares rise 5.32% premarket after Seegene unveils new diagnostic system and data analytics platform. - AInvest
Insight Molecular Diagnostics Insiders Increase Holdings Amidst Bullish Bets - AInvest
Insight Molecular Diagnostics Inc (IMDX) 재무 분석
Insight Molecular Diagnostics Inc (IMDX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.39%
자본화:
|
볼륨(24시간):